

Editorial Board



Hidehiko Nakagawa Editor-in-Chief Graduate School of

Pharmaceutical Sciences, Nagoya City University

The Chemical and Pharmaceutical

Bulletin(Chem. Pharm. Bull.) publishes Reviews, Current Topics, Communications, Regular Articles, and Notes monthly in print and online. Chem. Pharm. Bull. is devoted to the publication of original reports on cutting-edge research including creative approaches and novel ideas for sharing the urgent and valuable results with all readers of this journal. Chem. Pharm. Bull. covers various topics of current interest in all of chemistry and interfacing areas of pharmaceutical sciences. The main targeted subjects of Chem. Pharm. Bull. are as follows: Organic Chemistry, Medicinal Chemistry, Chemical Biology, In Silico Science, Analytical Chemistry, Physical Chemistry, Inorganic Chemistry, Physical Pharmacy, Pharmaceutical Engineering, Pharmacognosy, and Natural Product Chemistry.



Takashi Uehara Section Editor-in-Chief Faculty of Pharmaceutical Sciences, Okayama University



Yoshihisa Tomioka Section Editor-in-Chief Graduate School of Pharmaceutical Sciences, Tohoku University



Atsushi Matsuzawa Section Editor-in-Chief Graduate School of Pharmaceutical Sciences, Tohoku University

Masahiro Anada Editor Faculty of Pharmacy, Musashino University

Laurie M. H. Chan Editor University of Ottawa, Canada

Norbert A. Dencher Editor Technische Universit?t Darmstadt, Germany

Hitomi Fujishiro Editor Faculty of Pharmaceutical Sciences, Tokushima Bunri University

Hiroshi Hasegawa Editor Faculty of Pharmaceutical Sciences, Kobe Pharmaceutical University



Yasunori Iwao Section Editor-in-Chief School of Pharmaceutical Science, Wakayama Medical University



Shusuke Tada Section Editor-in-Chief School of Pharmaceutical Sciences, Toho University

Tomohiro Asai Editor School of Pharmaceutical Sciences, University of Shizuoka

Brian L. Crabtree Editor Mercer University College of Pharmacy, U.S.A.

Jeroen S. Dickschat Editor University of Bonn, Germany

Ken-ichi Fujita Editor School of Pharmacy, Showa University

Masayori Hagimori Editor Faculty of Pharmaceutical Sciences, Mukogawa Women's University

Toshiyuki Wakimoto Section Editor-in-Chief

Faculty of Phamaceutical Sciences, Hokkaido University



Masatoshi Tomi Section Editor-in-Chief Faculty of Pharmacy, Keio University

Xavier Decleves Editor University of Paris, France

Hideaki Fujii Editor School of Pharmacy, Kitasato University

Zezong Gu Editor University of Missouri School of Medicine, U.S.A.

Mitsuharu Hattori Editor Graduate School of Pharmaceurtical Sciences, Nagoya City University

Nobuaki Higashi

Editor Faculty of Pharmacy, Hoshi University

Katsuhisa Inoue Editor

School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

Tetsuro Ito Editor Department of Pharmacy, Faculty of Pharmacy, Gifu University of Medical Science

Kazunori Kadota Editor

Faculty of Pharmacy, Osaka Medical and Pharmaceutical University

Kazuyoshi Kawazoe Editor School of Pharmacy, Showa University

Kiyoyuki Kitaichi Editor Gifu Pharmaceutical University

Shinji Kosaka Editor Department of Pharmacy, Kagawa University Hospital

Toshiaki Kume Editor Faculty of Pharmaceutical

Sciences, University of Toyama

Nobuhiko Miura Editor Department of Health Science, Yokohama University of Pharmacy

Yuji Morita Editor

Faculty of Pharmaceutical Sciences, Meiji Pharmaceutical University

Kenjirou Higashi Editor Graduate School of Pharmaceutical Sciences, Chiba University

Ryuji Ikeda Editor Department of Pharmacy. University of Miyazaki Hospital

Junko Ishizaki Editor Faculty of Pharmacy, Institute of Medical, Pharmaceutical & Health Science, Kanazawa University

Keiji Izushi Editor Izushi Pharmacy Co., Ltd.

Katsuyuki Kaneda Editor Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University

Hiroaki Kimura Editor School of Pharmaceutical Sciences, Kyushu University of Health

Tatsuki Koike Editor Takeda Pharmaceutical Company Limited

Naoya Kumagai Editor Faculty of Pharmacy, Keio University

Wei Li Editor Faculty of Pharmaceutical Sciences, Toho University

Nobuaki Mizutani Editor College of Pharmacy, Kinjo Gakuin University

Yuichi Muraki Editor Department of Clinical Pharmacoepidemiology, Kyoto Koji Higai Editor Faculty of Pharmaceutical

Sciences, Toho University

Elichi Hinoi Editor Faculty of Pharmaceutical Sciences, Gifu Pharmaceutical University

Takuya Ito Editor Faculty of Pharmacy, Osaka Ohtani University

Takuya Iwamoto Editor Department of Pharmacy, Mie University Hospital

Makoto Kataoka Editor Faculty of Pharmaceutical Sciences, Setsunan University

Kentaro Kawai Editor Faculty of Pharmaceutical Sciences, Setsunan University

Takashi Kitahara Editor Graduate School of Medicine, Yamaguchi University

Akira Kotani Editor School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

Takashi Kuzuhara Editor Faculty of Pharmaceutical Sciences, Tokushima Bunri University

Osamu Morinaga Editor Daiichi University of Pharmacy

Keiichi Motoyama Editor Graduate School of Pharmaceutical Sciences, Kumamoto University Yoshihito Nakatani Editor Faculty of Pharmaceutical Sciences, Teikyo Helsei University

Makiya Nishikawa Editor Faculty of Pharmaceutical Sciences, Tokyo University of Science

Yukihiro Ohno Editor

Osaka Medical and Pharmaceutical University

Yoshiro Saito Editor National Institute of Health Sciences

Kumiko Sakai-Kato Editor School of Pharmacy, Kitasato University

Shigeki Shimba Editor Scoolo of Pharmacy, Nihon University

Michiru D. Sugawa Editor Charit? Universit?tsmedizin Berlin, Germany

Takayoshi Suzuki Editor The Institute of Scientific and Industrial Research, Osaka University

Yoshiyuki Tanabe Editor Faculty of Pharmaceutical Sciences, Yokohama University of Pharmacy

Futoshi Taura Editor Faculty of Pharmaceutical Sciences, University of Toyama

Kenichiro Todoroki Editor School of Pharmaceutical

Pharmaceutical University

Motohiro Nishida Editor Graduate School of Pharmaceutical Sciences, Kyushu University

Yasuko Obata Editor

Faculty of Pharmaceutical Sciences, Hoshi University

Tomofumi Okuno Editor Faculty of Pharmaceutical Sciences, Setsunan University

Nozomi Saito Editor Meiji Pharmaceutical University

Kenji Sakamoto Editor Faculty of Pharma-Sciences, Teikyo University

Tomoya Shiro Editor Drug Research Division, Sumitomo Dainippon Pharma Co., Ltd.

Changquan Calvin Sun Editor University of Minnesota, U.S.A.

Sayo Suzuki Editor Keio University Faculty of Pharmacy

Ryo Suzuki Editor Faculty of Pharma-Science, Teikyo University

Hikaru Tanaka Editor Faculty of Pharmaceutical Sciences, Toho University

Takaki Toda Editor Faculty of Pharmaceutical Sciences, Hokkaido University of Science Kiyofumi Ninomiya Editor Faculty of Pharmacy, Shujitsu University

Kohji Noguchi

Editor Faculty of Pharmaceutical Sciences, Tokyo University of Science

Shinya Oishi Editor Kyoto Pharmaceutical University

Kei-ichi Ozaki Editor Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts

Yasuo Sato Editor Yokohama University of Pharmacy

Chisato Shimanoe Editor Department of Pharmacy, Saga University Hospital

Nobukazu Shitan Editor Faculty of Pharmaceutical Sciences, Kobe Pharmaceutical University

Toyofumi Suzuki Editor School of Pharmacy, Nihon University

Tsutomu Takahashi Editor School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

Hiroyuki Tanaka Editor Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University

Chihiro Tohda Editor Institute of Natural Medicine, Sciences, University of Shizuoka

Takuhiro Uto Editor Faculty of Pharmaceutical Sciences, Nagasaki International University

Wataru Watanabe Editor Graduate School of Health Sciences, Kyushu University of Health and Welfare

Taku Yamaguchi Editor

Faculty of Pharmaceutical Sciences, Nagasaki International University

Junpei Yamanaka Editor Faculty of Pharmaceutical Sciences, Nagoya City University

Leslie Z. Benet Advisor University of California, U.S.A.

Mukund P. Sibi Advisor North Dakota State University, U.S.A.

Masafumi Ueda Editor Faculty of Pharmaceutical Sciences, Kobe Pharmaceutical University

Tirayut Vilaivan Editor Chulalongkom University, Thailand

Ken-ichi Yamada Editor Institute of Biomedical Sciences, Tokushima University

Katsuhiko Yamamoto Editor Takeda Pharmaceutical Co., Ltd.

Yoshiki Yanagawa Editor School of Pharmaceutical Sciences, Health Sciences University of Hokkaido

Henri B. Kagan Advisor University Paris-Sud, France

Amos B. Smith, III Advisor University of Pennsylvania, U.S.A.

University of Toyama

Naoki Utoguchi Editor Showa Pharmaceutical University

Kahon Wada Editor Faculty of Pharmaceutical Sciences, Doshisha Women's College

Shinji Yamaguchi Editor Faculty of Pharmaceutical Sciences, Telkyo University

Yoshihisa Yamamoto Editor Faculty of Pharmaceutical Sciences, Teikyo Heisel University

Yasuo Yoshioka Editor

Institute for Open and Transdisciplinary Research Initiatives, Osaka University

Manfred Schubert-Zsilavecz Advisor Johann Wolfgang Goethe University, Germany

Subject Area

Physics Chemistry Biology, Life Sciences and Basic Medicine Agriculture and Food Sciences Pharmaceutical Sciences Environmental Sciences

Other relevant information

Title Chemical and Pharmaceutical Bulletin

Publisher

The Pharmaceutical Society of Japan

Address

2-12-15, Shibuya, Shibuya-ku, Tokyo 150-0002, Japan

Contact email address

(Please change "(at)" into "@".) ronb(at)pharm.or.jp

URL

https://www.pharm.or.jp/eng/

Chemical and Pharmaceutical Bulletin

Online ISSN : 1347-5223 Print ISSN : 0009-2363 ISSN-L : 0009-2363

Journal home Advance online publication

Featured articles About the journal

Volume 57, Issue 8

Showing 1-23 articles out of 23 articles from the selected issue

Review

Naturally Occurring Iridoids, Secoiridoids and Their Bioactivity. An Updated Review, Part 3

Biswanath Dinda, Debashis Roy Chowdhury, Bikas Chandra Mohanta

Type: Review 2009 Volume 57 Issue 8 Pages 765-796 Published: August 01, 2009 Released: August 01, 2009

DOI https://doi.org/10.1248/cpb.57.765

JOURNALS FREE ACCESS

Show abstract

Download PDF (1425K)

Regular Articles

Anti Human Immunodeficiency Virus-1 (HIV-1) Agents 3. Synthesis and *in Vitro* Anti-HIV-1 Activity of Some *N*-AryIsulfonylindoles

Ling-Ling Fan, Wu-Qing Liu, Hui Xu, Liu-Meng Yang, Min Lv, Yong-Tang Z ...

Type: Regular Article 2009 Volume 57 Issue 8 Pages 797-800 Published: August 01, 2009 Released: August 01, 2009

DOI https://doi.org/10.1248/cpb.57.797

JOURNALS FREE ACCESS

Show abstract

Download PDF (97K)

Structure-Analgesic Activity Relationship Studies on the C18- and C19-Diterpenoid Alkaloids

DOI https://doi.org/10.1248/cpb.57.860

JOURNALS FREE ACCESS

Show abstract

Download PDF (74K)

Two New Phenylglycol Derivatives Isolated from Syringa reticulata var. mandshurica and Their Antifungal Activities

Qiong Ming Xu, Yan Li Liu, Xiao Ran Li, Yu Lin Feng, Shi Lin Yang

Type: Notes 2009 Volume 57 Issue 8 Pages 863-866 Published: August 01, 2009 Released: August 01, 2009

DOI https://doi.org/10.1248/cpb.57.863

JOURNALS FREE ACCESS

Show abstract

Download PDF (151K)

Delaumonones A and B, New Antiplasmodial Quassinoids from *Laumoniera bruceadelpha* Shiori Oshimi, Aki Takasaki, Yusuke Hirasawa, Takahiro Hosoya, Khalija ...

Type: Notes 2009 Volume 57 Issue 8 Pages 867-869 Published: August 01, 2009 Released: August 01, 2009

DDI https://doi.org/10.1248/cpb.57.867

JOURNALS FREE ACCESS

Show abstract

Download PDF (217K)

Two New Cucurbitane-Type Glycosides Obtained from Roots of Siraitia grosvenori SWINGLE

Dian-Peng Li, Mona El-Aasr, Tsuyoshi Ikeda, Misato Ogata, Hiroyuki Miy ...

Type: Notes 2009 Volume 57 Issue 8 Pages 870-872 Published: August 01, 2009 Released: August 01, 2009

DOI https://doi.org/10.1248/cpb.57.870

JOURNALS FREE ACCESS

Show abstract

Download PDF (92K)

Diketopiperazine Alkaloids from a Deep Ocean Sediment Derived Fungus Penicillium sp.

Delaumonones A and B, New Antiplasmodial Quassinoids from Laumoniera bruceadelpha

Shiori Oshimi,^{*a*} Aki Takasaki,^{*a*} Yusuke Hirasawa,^{*a*} Takahiro Hosoya,^{*a*} Khalijah Awang,^{*b*} A. Hamid A. Hadi,^{*b*} Wiwied Ekasari,^{*c*} Aty Widyawaruyanti,^{*c*} and Hiroshi Morita^{*,*a*}

^a Faculty of Pharmaceutical Sciences, Hoshi University; 2–4–41 Ebara, Shinagawa-ku, Tokyo 142–8501, Japan: ^b Department of Chemistry, Faculty of Science, University of Malaya; 50603 Kuala Lumpur, Malaysia: and ^c Faculty of Pharmacy, Airlangga University; Jalan Dharmawangsa Dalam, Surabaya 60286, Indonesia. Received February 28, 2009; accepted May 23, 2009; published online May 29, 2009

New quassinoids, delaumonones A (1) and B (2) have been isolated from the bark of *Laumoniera bruceadelpha* NOOTEBOOM (Simaroubaceae) and the structures were elucidated by 2D NMR analysis and a chemical correlation. Delaumonones showed an antimalarial activity against *Plasmodium falciparum*.

Key words quassinoid; delaumonone; antimalarial activity; Laumoniera bruceadelpha

Malaria is one of the crucial infectious disease in the world and continues to cause morbidity and mortality on a large scale in tropical countries.¹⁾ The antimalarial potential of compounds derived from plants is proven by examples such as quinine from *Cinchona* species and artemisinin from *Artemisia annua*.²⁾ The plants belonging to Simaroubaceae are known to contain various quassinoids with biological activities, such as antimalarial, antifeedant, anti-inflammatory, antiulcer, antipyretic, and cytotoxic activities.^{3–6)} Recent studies of numerous Simaroubaceae plants have highlighted good antimalarial activity of certain quassinoids against chloroquine-resistant strains of *Plasmodium falciparum*.⁷⁾ These results have prompted us to search for new quassinoids for possible antimalarial action.

With an aim to isolate additional antimalarial natural products,^{8–13)} purification of the extracts from the bark of *Laumoniera bruceadelpha* NOOTEBOOM (Simaroubaceae) collected in Malaysia led to isolate two new quassinoids, delaumonones A (1) and B (2). This paper describes the isolation and structural elucidation of 1 and 2 with an antimalarial activity against *P. falciparum*.

The bark of *L. bruceadelpha* (1.4 kg), which was collected in Malaysia, was extracted with MeOH, and the extract was partitioned between CHCl₃, *n*-BuOH, and H₂O. CHCl₃soluble materials were subjected to a silica gel column (CHCl₃/MeOH), and then an ODS column followed by ODS HPLC to afford delaumonones A (1, 11.9 mg) and B (2, 5.6 mg) together with isobrucein A (3, 307.0 mg)¹⁴⁾ and isobrucein B (4, 5.8 mg).¹⁵⁾ *n*-BuOH-soluble materials were subjected to an HP-20 column, and then a silica gel column (CHCl₃/MeOH), followed by ODS HPLC to afford delaumonone A (1, 15.0 mg) together with brucein D (5, 1.2 mg)¹⁶⁾ and yadanziolide A (6, 3.7 mg).¹⁷⁾

Delaumonone A (1), colorless solid, $[\alpha]_D^{20} + 20$ (c=1.0, MeOH), showed molecular formula, $C_{25}H_{32}O_{11}$, which was determined by HR-ESI-MS [m/z 531.1827 (M+Na)⁺, Δ – 1.5 mmu]. IR absorptions implied the presence of hydroxyl (3439 cm⁻¹) and carbonyl (1735, 1665 cm⁻¹) functionalities. ¹H- and ¹³C-NMR data are presented in Table 1. The ¹³C-NMR spectrum revealed 25 carbon signals due to five sp^2 quaternary carbons, three sp^3 quaternary carbons, one sp^2 methine, nine sp^3 methines, three methylenes, and four methyls. Among eight quaternary carbons (δ_C 45.7, 49.0,

* To whom correspondence should be addressed. e-mail: moritah@hoshi.ac.jp

81.0, 164.0, 168.2, 172.1, 173.8, 198.4), five quaternary carbons ($\delta_{\rm C}$ 81.0, 168.2, 172.1, 173.8, 198.4) were ascribed to those bearing an oxygen atom.

The molecular structure of 1 was deduced from extensive analyses of the two-dimensional NMR data, including the ¹H–¹H COSY, HMQC, and HMBC spectra in CD₃OD (Fig. 1). The ¹H–¹H COSY and HOHAHA spectra revealed connectivities of five partial structures **a** (C-3-C-4 and C-18), **b** (C-5-C-7), c (C-9 and C-11-C-12), d (C-14-C-15), and e (C-2'-C-5') as shown in Fig. 1. Connectivity of C-4 to C-5 was implied by an HMBC correlation for H₃-18 to C-5 ($\delta_{\rm C}$ 42.4). HMBC correlations were observed for H₃-19 to C-1 $(\delta_{\rm C} 81.5)$, C-5, C-9 $(\delta_{\rm C} 41.6)$, and C-10 $(\delta_{\rm C} 49.0)$, H-1 to C-2 ($\delta_{\rm C}$ 198.4), H-3 to C-1, suggesting that C-19 was connected through C-10 in a decalin ring system. HMBC cross peaks for H₂-20 to C-8 ($\delta_{\rm C}$ 45.7), C-12 ($\delta_{\rm C}$ 75.0), and C-13 ($\delta_{\rm C}$ 81.0) indicated that the presence of an ether bridge between C-13 and C-20. In addition, connection of unit c and a carboxylic acid through C-13 was also indicated by the HMBC correlations for H-12 to C-13 and C-21 ($\delta_{\rm C}$ 172.1). The presence of an isopentanoate at C-15 was implied by the HMBC correlations for H-15 and H-3' to C-1' ($\delta_{\rm C}$ 173.8). The presence of a δ -lactone ring characteristic of C₂₀ quassinoid skeleton was indicated by an HMBC correlation for H-14 to C-16 ($\delta_{\rm C}$ 168.2). Thus, the molecular structure of de-



© 2009 Pharmaceutical Society of Japan

laumonone A was elucidated to be 1.

The relative configuration of **1** was elucidated by NOESY correlations as depicted in the computer-generated three-dimensional drawing (Fig. 2). The NOESY correlations of H-1/H-5 and H-9, and H-9/H-5 and H-15 indicated that these protons at C-1, C-5, C-9, and C-15 were α -orientated. The β -orientation of H₃-19, H-7, and H-14, and α -orientation of H-11 were indicated by NOESY correlations of H-20/H-7 and H-14, and ³ $J_{\text{H-H}}$ coupling constant (3.2 Hz) of H-9/H-11.

Table 1. $^{1}\text{H-}$ and $^{13}\text{C-NMR}$ Data for Delaumonones A and B (1, 2) in CD_3OD at 300 K^{\prime\prime}

Position	$\delta_{ m H}$ (int.; mult.; J (Hz))		$\delta_{ m c}$	
	1	2	1	2
1	4.29 (1H, s)	3.89 (1H, s)	81.5	76.3
2			198.4	199.8
3	6.04 (1H, br s)	5.87 (1H, br s)	123.9	125.1
4			164.0	164.6
5	3.00 (1H, br d, 12.4)	3.06 (1H, br d, 12.7)	42.4	39.3
6a	1.96 (1H, m)	1.90 (1H, m)	27.8	28.9
6b	2.34 (1H, ddd, 14.8, 2.8, 2.8)	2.33 (1H, br d, 15.4)		
7	4.90 (1H, m)	4.90 (1H, m)	83.3	83.2
8			45.7	46.9
9	2.45 (1H, br d, 3.2)	2.70 (1H, br s)	41.6	35.3
10			49.0	44.7
11	4.72 (1H, br d, 5.2)	4.26 (1H, br d, 4.7)	73.8	72.5
12	4.20 (1H, br s)	4.20 (1H, br s)	75.0	76.4
13			81.0	84.0
14	3.26 (1H, m)	3.35 (1H, m)	51.2	51.2
15	6.25 (1H, m)	6.22 (1H, m)	68.7	66.0
16			168.2	169.6
18	1.97 (3H, s)	1.95 (3H, s)	21.2	22.5
19	1.19 (3H, s)	1.26 (3H, s)	10.1	14.8
20a	3.71 (1H, d, 7.6)	3.73 (1H, d, 7.6)	72.9	74.7
20b	4.68 (1H, d, 7.6)	4.71 (1H, d, 7.6)		
21			172.1	172.4
1'			173.8	173.1
2'	2.21 (2H, d, 6.8)	2.20 (2H, d, 6.8)	41.9	44.8
3'	2.07 (1H, m)	2.06 (1H, m)	25.2	26.7
4'	0.96 (3H, d, 6.8)	0.97 (3H, d, 6.6)	21.4	22.7
5'	0.97 (3H, d, 6.8)	0.98 (3H, d, 6.6)	21.4	22.7
OMe		3.79 (3H, s)		53.1

a) δ in ppm



Fig. 1. Selected 2D NMR Correlations for Delaumonone A (1)



Treatment of 1 with TMS-diazomethane afforded a methyl ester derivative, whose spectroscopic data and specific rotation were identical with those of isobrucein A (3).¹⁴⁾ Thus, the absolute configuration of delaumonone A was assigned as 1.

Delaumonone B (2), colorless solid, $[\alpha]_D^{20} + 18 (c=1.0, MeOH)$, showed molecular formula, $C_{26}H_{34}O_{11}$, which was determined by HR-ESI-MS $[m/z 523.2180, (M+H)^+, \Delta -0.1 \text{ mmu}]$. IR absorptions implied the presence of hydroxyl (3477 cm⁻¹) and carbonyl (1743, 1668 cm⁻¹) functionalities. ¹H- and ¹³C-NMR data are presented in Table 1. The ¹³C-NMR spectrum revealed 26 carbon signals due to five sp^2 quaternary carbons, three sp^3 quaternary carbons, one sp^2 methine, nine sp^3 methines, three methylenes, and five methyls. Among eight quaternary carbons (δ_C 44.7, 46.9, 84.0, 164.6, 169.6, 172.4, 173.1, 199.8), five quaternary carbons to those bearing an oxygen atom.

¹H–¹H COSY, HMQC, and HMBC spectra in Fig. 3 suggested that **2** had the same pentacyclic backbone framework as that of isobrucein A (**3**),¹⁴⁾ although the ¹H-NMR chemical shifts of H-1 ($\delta_{\rm H}$ 3.89), H-9 ($\delta_{\rm H}$ 2.70), and H-11 ($\delta_{\rm H}$ 4.26) in **2** were remarkably not identical to those [H-1 ($\delta_{\rm H}$ 4.17), H-9 ($\delta_{\rm H}$ 2.33), and H-11 ($\delta_{\rm H}$ 4.73)] in **3**, indicating that it was a stereoisomer of isobrucein A (**3**). The relative configuration of **2** was elucidated by NOESY correlations (Fig. 3). H-1 was assigned to be equatorial. NOESY cross peaks for H-1 to H₃-19 and H-11 were observed in the case of **2**, but not for **1** and **3**. This suggested that delaumonone B (**2**) was 1-*epi* form of isobrucein A (**3**). Thus, the relative configuration of delaumonone B (**2**) was assigned as shown.

Delaumonones A (1) and B (2) showed a potent *in vitro* antiplasmodial activity against *P. falciparum* 3D7 (IC₅₀ 1: 0.31 μ g/ml; 2: 0.60 μ g/ml) and cytotoxicity against HL-60 cells (IC₅₀ 1: 1.6 μ g/ml; 2: 2.4 μ g/ml). Among isolated quassinoids, isobrucein A¹⁴ (IC₅₀ 3: 0.024 μ g/ml) were more active than delaumonones A and B, but also showed a potent cytotoxicity against HL-60 cells (IC₅₀ 3: 0.0068 μ g/ml).



Fig. 2. Selected NOESY Correlations and Relative Configuration for Delaumonone A (1)





Delaumonones A and B had good selectivity index more than isobruce A, suggesting that the presence of β -orientation of the hydroxyl group at C-1 and the methoxy carbonyl group at C-21 contributed to a cytotoxicity more than an antiplasmodial activity.

In this study, we have isolated two new quassinoids, delaumonones A and B (1, 2) from the bark of *Laumoniera bruceadelpha*. Delaumonones showed an antimalarial activity against *P* falciparum. Cytotoxic activity against cancer cells was influenced by the nature of the C-21 side chain and of configuration at C-1, which was not much affected by an antimalarial activity against *P* falciparum.

Experimental

General Experimental Procedures Optical rotations were measured on a JASCO P-1030 polarimeter. UV spectra were recorded on a Shimadzu UV-250 spectrophotometer and IR spectra on a JASCO FTIR-230 spectrometer. Mass spectra were obtained with a Micromass LCT spectrometer. ¹H and 2D NMR spectra were recorded on a 600 MHz spectrometer at 300 K, while ¹³C-NMR spectra were measured on a 150 MHz spectrometer. Each NMR sample of delaumonones was prepared by dissolving in $30 \,\mu$ l of CD₃OD in 2.5 mm micro cells (Shigemi Co., Ltd.) and chemical shifts were reported using residual CD₃OD ($\delta_{\rm H}$ 3.31 and $\delta_{\rm C}$ 49.0) as internal standard. Standard pulse sequences were employed for the 2D NMR experiments. COSY, HO-HAHA, and NOESY spectra were measured with spectral widths of both dimensions of 4800 Hz, and 32 scans with two dummy scans were accumulated into 1 K data points for each of 256 t₁ increments. NOESY and HO-HAHA spectra in the phase sensitive mode were measured with a mixing time of 800 and 30 ms, respectively. For HMQC spectra in the phase sensitive mode and HMBC spectra, a total of 256 increments of 1 K data points were collected. For HMBC spectra with Z-axis PFG, a 50 ms delay time was used for long-range C–H coupling. Zero-filling to 1 K for F_1 and multiplication with squared cosine-bell windows shifted in both dimensions were performed prior to 2D Fourier transformation.

Plant Material The bark of *Laumoniera bruceadelpha* was collected at Mersing, Malaysia in 2001. The botanical identification was made by Mr. Teo Leong Eng, Faculty of Science, University of Malaya. Voucher specimens (KL4099) are deposited in the Herbarium of Chemistry Department, University of Malaya.

Extraction and Isolation The bark of L. bruceadelpha (1.4 kg), which was collected at Malaysia, was extracted with MeOH, and a part (40g) of the extract (126 g) was partitioned between CHCl₃, n-BuOH and H₂O. CHCl₃-soluble materials were subjected to a silica gel column (CHCl₂/MeOH, $1:0\rightarrow0:1$), in which a fraction eluted by CHCl₂/MeOH (40:1) was further purified on an ODS column with MeOH/H₂O $(0:1\rightarrow 1:0)$ followed by ODS HPLC (55% MeOH) to afford delaumonone B (2, 5.6 mg) together with isobrucein A (3, 307.0 mg)¹⁴⁾ and isobrucein B (4, 5.8 mg).¹⁵⁾ A fraction eluted by CHCl₃/MeOH (0:1) was further purified on ODS HPLC with 55% MeOH containing 0.1% TFA to afford delaumonone A (1, 11.9 mg). n-BuOH-soluble materials were subjected to an HP-20 column (H₂O/MeOH, $1:0\rightarrow0:1$), in which a fraction eluted 80% MeOH was further purified on a silica gel column (CHCl₂/MeOH, $1:0\rightarrow0:1$) and ODS HPLC (55% MeOH containing 0.1% TFA) to afford delaumonone A (1, 15.0 mg) together with brucein D (5, $1.2 \text{ mg})^{16}$ and yadanziolide A (6, 3.7 mg).¹⁷⁾ These compounds could also be isolated from EtOH extract of the same plant.

Delaumonone A (1): Colorless amorphous solid, $[\alpha]_D + 20$ (*c*=1.0, MeOH); IR (KBr) v_{max} 3439, 1735, and 1665 cm⁻¹; ¹H- and ¹³C-NMR (Table 1); ESI-MS (neg.) *m/z*: 507 (M-H)⁻; HR-ESI-TOF-MS (pos.) *m/z*: 531.1827 (M+Na)⁺, Calcd for C₂₅H₃₂O₁₁Na.

Delaumonone B (2): Colorless amorphous solid, $[\alpha]_D$ +18 (*c*=1.0, MeOH); IR (KBr) v_{max} 3477, 1743, and 1668 cm⁻¹; ¹H- and ¹³C-NMR (Table 1); ESI-MS (pos.) *m/z*: 545 (M+Na)⁺; HR-ESI-TOF-MS (pos.) *m/z*: 523.2180 (M+H)⁺, Calcd for C₂₆H₃₅O₁₁.

Conversion of Delaumonone A (1) to Isobrucein A (3) To a solution of delaumonone A (2.0 mg) in MeOH (0.2 ml) was added TMS-diazomethane (20 μ l), and the mixture was kept at r.t. for 3 h. After evaporation, a compound (1.9 mg), whose spectroscopic data and $[\alpha]_D$ value were identical with those of natural isobrucein A (3), was obtained.

Antiplasmodial Activity Human malaria parasites were cultured according to the method of Trager and Jensen.¹⁸⁾ The antimalarial activity of the isolated compounds was determined by the procedure described by Budimulja *et al.*¹⁹⁾ In brief, stock solutions of the samples were prepared in DMSO (final DMSO concentrations of <0.5%) and were diluted to the required concentration with complete medium (RPMI 1640 supplemented with 10% human plasma, 25 mM HEPES and 25 mM NaHCO₃) until the final concentrations of samples in culture plate wells were 10; 1; 0.1; 0.01; 0.001 µg/ml. The malarial parasite *P falciparum* 3D7 clone was propagated in a 24-well culture plates. Growth of the parasite was monitored by making a blood smear fixed with MeOH and stained with Geimsa stain. The antimalarial activity of each compound was expressed as an IC₅₀ value, defined as the concentration of the compound causing 50% inhibition of parasite growth relative to an untreated control.

The percentage of growth inhibition was expressed according to following equation: growth inhibition $\%=100-[(test parasitaemia/control parasitemia)\times100]$. Chloroqine: IC₅₀ 0.0061 µg/ml.

Cytotoxic Activity HL-60 (human blood premyelocytic leukemia) cell line was seeded onto 96-well microtiter plates at 1×10^4 cells per well. Cells were preincubated for 24 h at 37 °C in humidified atmosphere of 5% CO₂. Different concentrations of each compound (10 μ l) were added to the cultures, and then the cells were incubated at 37 °C for 48 h. On the third day, 15 μ l MTT solution (5 mg/ml) was added into each well of the cultured medium. After further 2 h of incubation, 100 μ l of 10% SDS–0.01 N HCl solution was added to each well and the formazan crystals in each well were dissolved by stirring with a pipette. The optical density measurements were made using a micropipette reader (Benchmark Plus microplate spectrometer, BIO-RAD) equipped with a two wavelengths system (550, 700 nm). In each experiment, three replicate of wells were prepared for each sample. The ratio of the living cells was determined based on the difference of the absorbance between those of samples and controls. These differences are expressed in percentage and cytotoxic activity was indicated as an IC₅₀ value.

Acknowledgments This work was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and a Grant from the Open Research Center Project. We also acknowledge the financial support provided by Faculty of Pharmacy, Airlangga University for antimalarial activity.

References

- 1) Wyler D. J., Clin. Infect. Dis., 16, 449-456 (1993).
- 2) Peters W., Br. Med. Bull., 32, 187–192 (1982).
- Bawm S., Matsuura H., Elkhateeb A., Nabeta K., Nonaka N., Oku Y., Katakura K., Vet. Parasitol., 158, 288–294 (2008).
- 4) Muhammad I., Samoylenko V., *Expert Opinion*, **2**, 1065–1084 (2007).
- Guo Z., Vangapandu S., Sindelar R. W., Walker L. A., Sindelar R. D., Curr. Med. Chem., 12, 173–190 (2005).
- Klocke J. A., Arisawa M., Honda S., Kinghorn A. D., Cordell G. A., Farnsworth N. R., *Experientia*, 41, 379–382 (1985).
- 7) Ang H. H., Chan K. L., Mak J. W., *Planta Med.*, **61**, 177–178 (1995).
- Koyama K., Hirasawa Y., Zaima K., Hoe T. C., Chan K. L., Morita H., Bioorg. Med. Chem., 16, 6483–6488 (2008).
- Hirasawa Y., Miyama S., Kawahara N., Goda Y., Rahman A., Ekasari W., Widyawaruyanti A., Indrayanto G., Zaini N. C., Morita H., *Hetero*cycles, **79**, 1107–1112 (2009).
- Hirasawa Y., Arai H., Zaima K., Oktarina R., Rahman A., Ekasari W., Widyawaruyanti A., Indrayanto G., Zaini N. C., Morita H., *J. Nat. Prod.*, **72**, 304–307 (2009).
- Sekiguchi M., Hirasawa Y., Zaima K., Hoe T. C., Chan K.-L., Morita H., *Heterocycles*, **75**, 2283–2288 (2008).
- Sekiguchi M., Hirasawa Y., Zaima K., Hoe T. C., Chan K.-L., Morita H., *Heterocycles*, **76**, 867–874 (2008).
- Zaima K., Matsuno Y., Hirasawa Y., Rahman A., Indrayanto G., Zaini N. C., Morita H., *Heterocycles*, 75, 2535–2540 (2008).
- Polonsky J., Baskevitch-Varon Z., Sevenet T., *Experientia*, **31**, 1113– 1114 (1975).
- 15) Okano M., Fukamiya N., Aratani T., J. Nat. Prod., 48, 972–975 (1985).
- 16) Li X., Wu L., Konda Y., Iguchi M., Takahashi H., Harigaya Y., Onda M., J. Heterocycl. Chem., 26, 493—501 (1989).
- 17) Lee K. H., Imakura Y., Sumida Y., Wu R. Y., Iris H., Huang H. C., J. Org. Chem., 44, 2180—2185 (1979).
- 18) Trager W., Jensen J. B., Science, 193, 673-675 (1976).
- Budimulja A. S., Syafruddin T. P., Wilairat P., Marzuki S., Mol. Biochem. Parasitol., 84, 137–141 (1997).

				developed by scimago:	III SCIMAGO INSTITUTIONS RANKINGS			
		SJR Scimago Journal & Country Rank		Enter Journal Tit	ie, ISSN or Publisher Name Q			
		Home	Journal Rankings Country Rankings Viz Tools Help	About Us				
Chemical and Pharmaceutical Bulletin								
Chemical and Pharmaceutical Bulletin		COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX			
		Japan	Chemistry	Pharmaceutical	05			
00	Chemistry	Universities and research	Chemistry (miscellaneous)	Society of Japan	95			
02	(miscellaneous)	institutions in Japan	└─ Medicine (miscellaneous)					
	best quartile		Pharmacology, Toxicology and Pharmaceutics					
CID 2021		PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION			
SJR 2021	•	Journals	00092363, 13475223	1958-2021	Homepage			
0.38					How to publish in			
powe	red by scimagojr.com				this journal			
					ione@promiside			
C	CODUC Draview		Author Creater Courses	Q Country	Circuit.			
E DE	copus preview		Q Author Search Sources ()	m Create	account			
Sourc	o dotaile			Feedbar				
Sourc	le uetalls			reeubau	ck / Compare sources /			
				CiteScore 202	1			
Chemical and Pharmaceutical Bulletin					0			
Formerly known as	s: Pharmaceutical bulletin			5.0				
Scopus coverage years: from 1958 to Present								
Publisher: F	Pharmaceutical Society of Jap	SJR 2021	(i)					
ISSN: 0009-	-2363 E-ISSN: 1347-5223	0.570						
Subject area:								
Source type: Journal					0			
View all desurgents > Cut desurgents all at ID Courts accurs list Source Homessee								
View all documents > Set document alert								
CiteScore	CiteScore rank & trend	Scopus content coverage						
		1 0						
					v			
i Impr	roved CiteScore methodolog	ξγ			~			
CiteSo	core 2021 counts the citations receiv	ved in 2018-2021 to articles, reviews, conference pap	ers, book chapters and data					
paper	s published in 2018-2021, and divid	des this by the number of publications published in 2	2018-2021. Learn more >					
CiteScore	e 2021	CiteScoreTracker 2022 ①						
$30 - \frac{2,002 \text{ Citations } 2018 - 2021}{26}$								
663 Documents 2018 - 2021 2.0 560 Documents to date								
Calculated on 05 May, 2022 Last updated on 06 June, 2022 • Updated monthly								
CiteScore	rank 2021 @							
	anan in an in the second s							
Category Rank Percentile								
Chemistry	#100/400	Clet						
└─ General Che	emistry #199/409							
Pharmacology, Toxicology and								
Pharmaceutics #97/154 37th								
Drug Discov	very							